Tissue Regenix Group PLC DermaPure® breaks through $1m sales mark
January 20 2016 - 2:00AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
20 January 2016
Tissue Regenix Group plc
("Tissue Regenix" or "The Group")
DermaPure(R) breaks through $1m sales mark
York, 20 January 2016 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "The Group") the regenerative medical devices
company announces its dCELL(R) woundcare product DermaPure(R) has
now surpassed the $1m sales mark, following its commercialisation
in the US. DermaPure(R) was issued the Medicare 'Q' code for
reimbursement in November 2014, which became effective as of
January 1(st) 2015, and is now available to almost 65% of Medicare
beneficiaries, spanning 31 states.
The product is primarily aimed at the treatment of chronic
wounds associated with diabetes. Approximately 10% of the American
population are currently suffering from Type I or Type 2 diabetes,
making the prevalence of hard to heal wounds, a common side effect
of the disease, increase rapidly. In addition, DermaPure(R) is
being used in a number of other varied clinical settings, treating
conditions from pressure ulcers to frostbite. It is expected that
Tissue Regenix, Woundcare Inc. will now develop this same dCELL(R)
technology into products addressing other applications.
Greg Bila, President of Tissue Regenix Woundcare, Inc.
commented, "Since launch in 2014, the uptake of DermaPure(R) within
a competitive marketplace has been highly encouraging and we are
thrilled to announce the first $1m of sales. We are finding that it
is the intrinsic qualities of DermaPure(R) which make it effective
and differentiate it from other products available. Unlike cell
based products, DermaPure(R) signals the body to redirect the
patient's own cells to the affected area, allowing the body to
regenerate healthy tissue. I would like to thank our clinical
affairs and sales teams, whose hard work has allowed us to reach
this milestone, and look forward to seeing continued momentum in
the coming year."
For more information:
Tissue Regenix Group plc Tel: 01904
Caitlin Pearson - Corporate Communications 567 609
Officer
Jefferies International Ltd Tel: 020 7029
Simon Hardy / Harry Nicholas 8000
Tulchan Communications Tel: 020 7353
James Macey-White / Matt low 4200
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLMLTMBABBIF
(END) Dow Jones Newswires
January 20, 2016 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024